Antisense Therapeutics (ASX:ANP) has announced that five patients have completed their 24 weeks of dosing in the phase 2 clinical trial of the company's immunomodulatory therapy, ATL1102, for Duchenne Muscular Dystrophy (DMD).
The company said the remaining four patients are at various points within the treatment phase of the study.
No Serious Adverse Events (SAE’s) have been reported to date, it said, adding the dosing of all patients in the trial will be completed in early November 2019.
The open-label six-month dosing trial of ATL1102 in nine non-ambulant patients with DMD aged between 10 and 18 years is being conducted at the neuromuscular centre of the Royal Children’s Hospital in Melbourne. The hospital operates the largest clinic in the southern hemisphere treating children with DMD.
ATL1102 is being developed as a novel treatment for the inflammation that exacerbates muscle fibre damage in DMD patients, currently treated with corticosteroids.
The primary endpoints of the trial relate to the safety and tolerability of ATL1102. The efficacy of ATL1102 in DMD will also be assessed in terms of its effects on disease processes and progression - the upper limb strength and function of the boys.
Antisense said it expects to report trial results shortly after the completion of dosing.
According to CEO Mark Diamond, ”We are pleased to have more than half of patients in the trial having completed dosing with no SAE’s reported to date and to be on track for completion of the treatment phase of the trial in the next quarter.”